Clincosm LogoSign in Get a demo

Surgical Therapy and Survival in HCC/ C.F. Zhang et al.

Sponsor
Linzhu Zhai (Other)
Overall Status
Completed
CT.gov ID
NCT04820712
Collaborator
(none)
664
Enrollment
1
Location
4
Actual Duration (Months)
165.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study utilizes a new method to explore compare the overall survival (OS) and cancer-specific survival (CSS) in patients aged 18-45 years with stage I-II HCC who underwent different types of surgery. The SEER database, which is one of the most comprehensive and authoritative databases concerning cancer, was used to estimate the survival benefit of patients who underwent local tumor destruction (LTD), wedge or segmental resection (WSR), lobectomy resection (LR), liver transplantation (LT), or non-surgery. This study discovered surgery offered a survival benefit compared with non-surgery for young patients with stage I-II HCC. Furtherly, LT is associated with superior survival than WSR, LR and LTD in those patients. Our results facilitate the selection of surgical strategies.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis. Therefore, the current study was deemed to be exempt from Institutional Review Board approval and the need for informed consent was waived. The submitted magazine requires registration on the website, so this operation is needed.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    664 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Surgical Therapy and Survival in Young Patients With Stage I-II Hepatocellular Carcinoma: A Retrospective Cohort Study
    Actual Study Start Date :
    Sep 1, 2020
    Actual Primary Completion Date :
    Jan 1, 2021
    Actual Study Completion Date :
    Jan 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Overall survival [2004.1.1-2013.12.31]

      Overall survival was defined as the duration between the surgery and death or the last follow-up

    Secondary Outcome Measures

    1. Cancer-specific survival [2004.1.1-2013.12.31]

      Cancer-specific survival was defined as the period between the surgery and death due to cancer to reduce the impact of life-threatening comorbidities.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Patients were diagnosed with colorectal cancer only;

    2. Patients with simultaneous metastasis of liver and lung cancer cells;

    3. Patients without metastasis resection;

    4. whether they underwent palliative primary tumor resection was known;

    5. Their cause of death was known;

    6. Their survival time were known and greater than 0 month;

    7. Patients were diagnosed with microscopic confirmation.

    Exclusion Criteria:
    • No

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 linzhu Zhai Guangzhou Guangdong China 510405

    Sponsors and Collaborators

    • Linzhu Zhai

    Investigators

    None specified.

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Linzhu Zhai, Director, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
    ClinicalTrials.gov Identifier:
    NCT04820712
    Other Study ID Numbers:
    • FirstAHGTCMU
    First Posted:
    Mar 29, 2021
    Last Update Posted:
    Apr 1, 2021
    Last Verified:
    Mar 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Carcinoma
    Carcinoma, Hepatocellular

    Study Results

    No Results Posted as of Apr 1, 2021